



Table S1. Association between TRK expression and clinicopathological features.

Comparison	Variable	Groups		p-value
Pan-TRK expression		Negative pan-TRK	Positive pan-TRK	
	N	42	34	-
	Age, years: median (IQR)	75 (68-83)	69 (64-78)	0.06
	Males: n (%)	17 (40)	19 (56)	0.29
	Primary site, n (%):			0.22
	Extremities	21 (50)	24 (71)	
	Eyelid	3 (7)	0	
Membranous TRK expression pattern	HN	13 (31)	7 (20)	
	Trunk	5 (12)	3 (9)	
	MCPyV positive: n (%)	26 (62)	17 (50)	0.42
		Not-membranous TRK expression	Membranous TRK expression pattern	
	N	15	19	-
	Age, years: median (IQR)	67 (62-77)	70 (65-81)	0.37
	Males: n (%)	9 (60)	10 (53)	0.74
Cytoplasmic TRK expression pattern	Primary site, n (%):			0.11
	Extremities	10 (67)	14 (74)	
	Eyelid	2 (13)	5 (26)	
	HN	3 (20)	0 (0)	
	Trunk			
	MCPyV positive: n (%)	8 (53)	9 (47)	0.99
		Not-cytoplasmic TRK expression	Cytoplasmic TRK expression	
Dot-like TRK expression pattern	N	5	29	-
	Age, years: median (IQR)	66 (63-69)	70 (65-78)	0.73
	Males: n (%)	3 (60)	16 (55)	0.99
	Primary site, n (%):			0.99
	Extremities	4 (80)	20 (69)	
	Eyelid	1 (20)	6 (21)	
	HN	0 (0)	3 (10)	
Dot-like TRK expression pattern	Trunk			
	MCPyV positive: n (%)	1 (20)	16 (55)	0.34
		Not dot-like TRK expression	Dot-like TRK expression	
	N	23	10	-
	Age, years: median (IQR)	67 (62-79)	72 (66-77)	0.38
	Males: n (%)	14 (61)	4 (40)	0.45
	Primary site, n (%):			0.72
Nuclear TRK expression pattern	Extremities	15 (65)	8 (80)	
	Eyelid	6 (26)	1 (10)	
	HN	2 (9)	1 (10)	
	Trunk			
	MCPyV positive: n (%)	13 (57)	4 (40)	0.46
		Not-nuclear TRK expression	Nuclear TRK expression	
	N	28	6	-
Nuclear TRK expression pattern	Age, years: median (IQR)	69 (62-78)	68 (66-74)	0.79

	Males: n (%)	15 (54)	4 (67)	0.67
	Primary site, n (%):			0.78
	Extremities	20 (72)	4 (66)	
	Eyelid	6 (21)	1 (17)	
	HN	2 (7)	1 (17)	
	Trunk			
	MCPyV positive: n (%)	17 (61)	0 (0)	0.02

IQR: interquartile range. Information on dot-like TRK expression pattern was not available in one patient.

Table S2. Analysis of survival.

Variable	Recurrence/progression-free survival		Overall survival	
	Hazard ratio (95% confidence interval)	p-value	Hazard ratio (95% confidence interval)	p-value
Negative pan-TRK Positive pan-TRK	Reference 1.39 (0.69 to 2.77)	0.36	Reference 1.01 (0.56 to 1.84)	0.97
Not-membranous TRK expression Membranous TRK expression	Reference 1.03 (0.38 to 2.76)	0.96	Reference 1.02 (0.41 to 2.53)	0.97
Not-cytoplasmic TRK expression Cytoplasmic TRK expression	Reference 0.58 (0.16 to 2.039)	0.39	Reference 0.61 (0.20 to 1.87)	0.38
Not dot-like TRK expression Dot-like TRK expression	Reference 0.76 (0.24 to 2.40)	0.64	Reference 1.41 (0.51 to 3.90)	0.51
Not-nuclear TRK expression Nuclear TRK expression	Reference 0.34 (0.05 to 2.60)	0.30	Reference 2.14 (0.76 to 6.03)	0.15

Table S3. List of detectable gene alterations with the Easy PGX ready NTRK fusion test.

<i>NTRK1</i> exon 9-10	<i>TFG-NTRK1</i> T5:N9 <i>NFASC-NTRK1</i> N20:N10 <i>NFASC-NTRK1</i> N21:N10
<i>NTRK1</i> exon 10	<i>SQSTM1-NTRK1</i> S4:N10 <i>TFG-NTRK1</i> T5:N10 <i>TPM3-NTRK1</i> T7:N10 <i>TPR-NTRK1</i> T21:N10 <i>TRIM63-NTRK1</i> T8:N10
<i>NTRK1</i> exon 11-12del	<i>BCAN-NTRK1</i> B13:N11 <i>LMNA-NTRK1</i> L11del178:N11 <i>LMNA-NTRK1</i> L2:N11 <i>PPL-NTRK1</i> P22del2181:N11 <i>TPR-NTRK1</i> T6del122:N12del99
<i>NTRK1</i> exon 12	<i>MPRIP-NTRK1</i> M21:N12 <i>MPRIP-NTRK1</i> M18:N12 <i>MPRIP-NTRK1</i> M14:N12 <i>SCYL3-NTRK1</i> S11:N12 <i>TPM3-NTRK1</i> T7:N12 <i>TPR-NTRK1</i> T6:N12
<i>NTRK2</i> exon 12-15	<i>AFAP1-NTRK2</i> A13:N12 <i>VCL-NTRK2</i> V16:N12 <i>TLE4-NTRK2</i> T7:N15 <i>TRIM24-NTRK2</i> T12:N15
<i>NTRK2</i> exon 16-17	<i>AGBL4-NTRK2</i> A6:N16 <i>QKI-NTRK2</i> Q6:N16 <i>SQSTM1-NTRK2</i> S4:N16 <i>STRN-NTRK2</i> S3:N16 <i>SQSTM1-NTRK2</i> S4:N17
<i>NTRK3</i> exon 14	<i>ETV6-NTRK3</i> E4:N14 <i>ETV6-NTRK3</i> E5:N14
<i>NTRK3</i> exon 15	<i>ETV6-NTRK3</i> E4:N15 <i>ETV6-NTRK3</i> E5:N15